Anti-tumor effect of combining CC chemokine 22 and an anti-CD25 antibody on myeloma cells implanted subcutaneously into mice

Molecular Medicine Reports

Volumn 2, Issue 5, 2009, Pages 773-777

  Cho, Seiji ^a,b   Koizumi, Keiichi ^b   Takeno, Nobuhiro ^b   Kato, Shinichiro ^b   Yamada, Miyuki ^b   Hashimoto, Isaya ^a   Sakurai, Hiroaki ^b   Tsukada, Kazuhiro ^a   Saiki, Ikuo ^b  

^a TOYAMA MEDICAL AND PHARMACEUTICAL UNIVERSITY   (Japan)

^b UNIVERSITY OF TOYAMA   (Japan)

Author keywords

CCL22; Chemokine; Gene therapy; Regulatory T cells

Indexed keywords

CD4 ANTIGEN; CHEMOKINE RECEPTOR CCR4; INTERLEUKIN 2 RECEPTOR ALPHA; LYMPHOCYTE ANTIBODY; MACROPHAGE DERIVED CHEMOKINE; PC61 5.3 CD25 T CELL SPECIFIC ANTIBODY; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIGEN EXPRESSION; ARTICLE; CANCER CELL CULTURE; CANCER COMBINATION CHEMOTHERAPY; CANCER INHIBITION; CANCER MODEL; CD25+ T LYMPHOCYTE; CD4+ T LYMPHOCYTE; CONTROLLED STUDY; IMMUNOMODULATION; MALE; MOUSE; MULTIPLE MYELOMA; MYELOMA CELL; NONHUMAN; PROTEIN EXPRESSION; REGULATORY T LYMPHOCYTE; SYSTEMATIC REVIEW; TUMOR GROWTH; TUMOR REGRESSION;

MUS;

EID: 69249202457     PISSN: 17912997     EISSN: 17913004     Source Type: Journal    
DOI: 10.3892/mmr_00000171     Document Type: Article

References (25)

1. Yoshie O, Imai T and Nomiyama H: Novel lymphocyte-specific CC chemokines and their receptors. J Leukoc Biol 62: 634-644, 1997. (Pubitemid 27519774)
2. Yoshie O, Imai T and Nomiyama H: Chemokines in immunity. Adv Immunol 78: 57-110, 2001.
3. Cairns CM, Gordon JR, Li F, Baca-Estrada ME, Moyana T and Xiang J: Lymphotactin expression by engineered myeloma cells drives tumor regression: mediation by CD4+ and CD8+ T cells and neutrophils expressing XCR1 receptor. J Immunol 167: 57-65, 2001. (Pubitemid 32567761)
4. Maric M and Liu Y: Strong cytotoxic T lymphocyte responses to a macrophage inflammatory protein 1 alpha-expressing tumor: linkage between inflammation and specific immunity. Cancer Res 59: 5549-5553, 1999. (Pubitemid 29526472)
5. Godiska R, Chantry D, Raport CJ, Sozzani S, Allavena P, Leviten D, Mantovani A and Gray PW: Human macrophage-derived chemokine (MDC), a novel chemoattractant for monocytes, monocyte derived dendritic cells, and natural killer cells. J Exp Med 185: 1595-1604, 1997. (Pubitemid 27203256)
6. Imai T, Chantry D, Raport CJ, Wood CL, Nishimura M, Godiska R, Yoshie O and Gray PW: Macrophage-derived chemokine is a functional ligand for the CC chemokine receptor 4. J Biol Chem 273: 1764-1768, 1998. (Pubitemid 28133708)
7. Vestergaard C, Yoneyama H, Murai M, Nakamura K, Tamaki K, Terashima Y, Imai T, Yoshie O, Irimura T, Mizutani H and Matsushima K: Overproduction of Th2-specific chemokines in NC/Nga mice exhibiting atopic dermatitis-like lesions. J Clin Invest 104: 1097-1105, 1999. (Pubitemid 29536320)
8. Gonzalo JA, Pan Y, Lloyd CM, Jia GQ, Yu G, Dussault B, Power CA, Proudfoo A, Coyle AJ, Gearing D and Gutierrez-Ramos JC: Mouse monocyte-derived chemokine is involved in airway hyperreactivity and lung inflammation. J Immunol 163: 403-411, 1999. (Pubitemid 29295867)
9. Guo J, Wang B, Zhang M, Chen T, Yu Y, Regulier E, Homann HE, Qin Z, Ju DW and Cao X: Macrophage-derived chemokine gene transfer results in tumor regression in murine lung carcinoma model through efficient induction of antitumor immunity. Gene Ther 9: 793-803, 2002. (Pubitemid 34679307)
10. Nakamura ES, Koizumi K, Kobayashi M, Saitoh Y, Arita Y, Nakayama T, Sakurai H, Yoshie O and Saiki I: RANKL-induced CCL22/macrophage-derived chemokine produced from osteoclasts potentially promotes the bone metastasis of lung cancer expressing its receptor CCR4. Clin Exp Metastasis 23: 9-18, 2006. (Pubitemid 44576775)
11. Gao JQ, Sugita T, Kanagawa N, Iida K, Okada N, Mizuguchi H, Nakayama T, Hayakawa T, Yoshie O, Tsutsumi Y, Mayumi T and Nakagawa S: Anti-tumor responses induced by chemokine CCL19 transfected into an ovarian carcinoma model via fiber-mutant adenovirus vector. Biol Pharm Bull 28: 1066-1070, 2005. (Pubitemid 40880316)
12. Berencsi K, Meropol NJ, Hoffman JP, Sigurdson E, Giles L, Rani P, Somasundaram R, Zhang T, Kalabis J, Caputo L, Furth E, Swoboda R, Marincola F and Herlyn D: Colon carcinoma cells induce CXCL11-dependent migration of CXCR3-expressing cytotoxic T lymphocytes in organotypic culture. Cancer Immunol Immunother 56: 359-370, 2007. (Pubitemid 46043214)
13. Imai T, Baba M, Nishimura M, Kakizaki M, Takagi S and Yoshie O: The T cell-directed CC chemokine TARC is a highly specific biological ligand for CC chemokine receptor 4. J Biol Chem 272: 15036-15042, 1997. (Pubitemid 27251781)
14. Tang HL and Cyster JG: Chemokine up-regulation and activated T cell attraction by maturing dendritic cells. Science 28: 819-822, 1999. (Pubitemid 29291350)
15. Vulcano M, Albanesi C, Stoppacciaro A, Bagnati R, D'Amico G, Struyf S, Transidico P, Bonecchi R, Prete AD, Allavena P, Ruco LP, Chiabrando C, Girolomoni G, Mantovani A and Sozzani S: Dendritic cells as a major source of macrophage-derived chemokine/CCL22 in vitro and in vivo. Eur J Immunol 31: 812-822, 2001. (Pubitemid 32241777)
16. Pal R, Garzino-Demo A, Markham PD, Burns J, Brown M, Gallo RC and DeVico AL: Inhibition of HIV-1 infection by the B-chemokine MDC. Science 278: 695-698, 1997. (Pubitemid 27464969)
17. Kanagawa N, Niwa M, Hatanaka Y, Tani Y, Nakagawa S, Fujita T, Yamamoto A and Okada N: CC-chemokine ligand 17 gene therapy induces tumor regression through augmentation of tumor-infiltrating immune cells in a murine model of preexisting CT26 colon carcinoma. Int J Cancer 121: 2013-2022, 2007. (Pubitemid 47463165)
18. Huang H, Li F, Gordon JR and Xiang J: Synergistic enhancement of antitumor immunity with adoptively transferred tumor-specific CD4+ and CD8+ T cells and intratumoral lymphotactin transgene expression. Cancer Res 62: 2043-2051, 2002. (Pubitemid 34408450)
19. Koizumi K, Hojo S, Akashi T, Yasumoto K and Saiki I: Chemokine receptors in cancer metastasis and cancer cell-derived chemokines in host immune response. Cancer Sci 98: 1652-1658, 2007. (Pubitemid 47487897)
20. Soria G and Ben-Baruch A: The inflammatory chemokines CCL2 and CCL5 in breast cancer. Cancer Lett 267: 271-285, 2008.
21. Ueno T, Toi M , Saji H, Muta M, Bando H, Kuroi K, Koike M, Inadera H and Matsushima K: Significance of macrophage chemoattractant protein-1 in macrophage recruitment, angiogenesis, and survival in human breast cancer. Clin Cancer Res 6: 3282-3289, 2000. (Pubitemid 30637758)
22. Slettenaar VI and Wilson JL: The chemokine network: a target in cancer biology? Adv Drug Deliv Rev 58: 962-974, 2006.
23. Niens M, Visser L, Nolte IM, van der Steege G, Diepstra A, Cordano P, Jarrett RF, te Meerman GJ, Poppema S and van den Berg A: Serum chemokine levels in Hodgkin lymphoma patients: highly increased levels of CCL17 and CCL22. Br J Haematol 140: 52736, 2008.
24. Mizukami Y, Kono K, Kawaguchi Y, Akaike H, Kamimura K, Sugai H and Fujii H: CCL17 and CCL22 chemokines within tumor microenvironment are related to accumulation of Foxp31 regulatory T cells in gastric cancer. Int J Cancer 122: 2286-2293, 2008. (Pubitemid 351542333)
25. Ishida T and Ueda R: CCR4 as a novel molecular target for immunotherapy of cancer. Cancer Sci 97: 1139-1146, 2006. (Pubitemid 44430638)